MXPA06001273A - Compuestos novedosos. - Google Patents
Compuestos novedosos.Info
- Publication number
- MXPA06001273A MXPA06001273A MXPA06001273A MXPA06001273A MXPA06001273A MX PA06001273 A MXPA06001273 A MX PA06001273A MX PA06001273 A MXPA06001273 A MX PA06001273A MX PA06001273 A MXPA06001273 A MX PA06001273A MX PA06001273 A MXPA06001273 A MX PA06001273A
- Authority
- MX
- Mexico
- Prior art keywords
- ring
- optionally substituted
- fused heterobicyclic
- group
- unsaturated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Un compuesto de la formula (I): (ver formula (I)) en donde el Anillo A y el Anillo B son, (1) el Anillo A es un anillo monociclico, heterociclico no saturado, sustituido opcionalmente, y el Anillo B es un anillo monociclico, heterociclico no saturado, sustituido opcionalmente, un anillo heterobiciclico fusionado no saturado, sustituido opcionalmente, o un anillo de benceno sustituido opcionalmente, (2) el Anillo A es un anillo de benceno sustituido opcionalmente, y el Anillo B es un anillo monociclico, heterociclico no saturado, sustituido opcionalmente, un anillo heterobiciclico fusionado no saturado, sustituido opcionalmente, o un anillo de benceno sustituido opcionalmente, o (3) el Anillo A es un anillo heterobiciclico fusionado no saturado, sustituido opcionalmente, en donde el grupo -NR- y el grupo -CH2- estan ambos en el mismo anillo del anillo heterobiciclico no saturado fusionado, y el Anillo B es un anillo monociclico, heterociclico no saturado, sustituido opcionalmente, un anillo heterobiciclico fusionado no saturado, sustituido opcionalmente, o un anillo de benceno sustituido opcionalmente; y R es un atomo de hidrogeno, un grupo alquilo inferior, un grupo alcanoilo inferior o un grupo alcoxicarbonilo inferior, o una sal farmaceuticamente aceptable del mismo, o un profarmaco del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49152303P | 2003-08-01 | 2003-08-01 | |
PCT/JP2004/011311 WO2005012321A1 (en) | 2003-08-01 | 2004-07-30 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06001273A true MXPA06001273A (es) | 2006-04-11 |
Family
ID=34115512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06001273A MXPA06001273A (es) | 2003-08-01 | 2004-07-30 | Compuestos novedosos. |
Country Status (18)
Country | Link |
---|---|
US (1) | US7521430B2 (es) |
EP (1) | EP1654269B1 (es) |
JP (1) | JP4717811B2 (es) |
KR (1) | KR101101500B1 (es) |
CN (2) | CN1829728A (es) |
AU (1) | AU2004260760B2 (es) |
BR (1) | BRPI0413233A (es) |
CA (1) | CA2534022C (es) |
EA (1) | EA011025B1 (es) |
ES (1) | ES2527053T3 (es) |
IL (1) | IL173051A (es) |
MX (1) | MXPA06001273A (es) |
NO (1) | NO333679B1 (es) |
NZ (1) | NZ545305A (es) |
TW (1) | TWI377209B (es) |
UA (5) | UA86042C2 (es) |
WO (1) | WO2005012321A1 (es) |
ZA (2) | ZA200601686B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
ME00411B (me) * | 2003-08-01 | 2011-10-10 | Tanabe Seiyaku Co | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma |
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
TWI365186B (en) | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
JP5073948B2 (ja) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
JP5298025B2 (ja) * | 2006-12-04 | 2013-09-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体 |
US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
RS56990B1 (sr) | 2007-09-10 | 2018-05-31 | Janssen Pharmaceutica Nv | Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
CA2725047A1 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
EA018492B1 (ru) | 2008-08-28 | 2013-08-30 | Пфайзер Инк. | Диоксабицикло[3.2.1]октан-2,3,4-триольные производные |
US20110230403A1 (en) * | 2008-09-19 | 2011-09-22 | Novartis Ag | Glycoside derivatives and uses thereof |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
PL2451797T3 (pl) | 2009-07-10 | 2013-08-30 | Janssen Pharmaceutica Nv | Proces krystalizacji dla 1-(ß-D-glukopiranozylo)-4-metylo-3-[5-(4-fluorofenylo)-2-tienylometylo]benzenu |
WO2011047113A1 (en) * | 2009-10-14 | 2011-04-21 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
GEP20146104B (en) | 2009-11-02 | 2014-05-27 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
BR112012028857B1 (pt) | 2010-05-11 | 2021-02-09 | Janssen Pharmaceutica Nv | Composições farmacêuticas administráveis por via oral que compreendem derivados de 1- (beta-d glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt |
CN103596944B (zh) | 2011-04-13 | 2017-02-22 | 詹森药业有限公司 | 可用作sglt2的抑制剂的化合物的制备方法 |
TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
US20160002276A1 (en) * | 2013-02-26 | 2016-01-07 | Mitsubishi Tanabe Pharma Corporation | METHOD FOR PRODUCING a-HALO-TETRAACYL-GLUCOSE |
CN103896930B (zh) * | 2014-04-02 | 2016-08-17 | 安徽联创生物医药股份有限公司 | 卡格列净半水合物药用晶型的制备方法 |
ES2711804T3 (es) | 2014-05-27 | 2019-05-07 | Glenmark Pharmaceuticals Ltd | Proceso para preparación de canagliflozina |
CN104045673B (zh) * | 2014-06-06 | 2017-01-18 | 安徽省食品药品检验研究院 | 双‑三氮唑缀合的假二糖衍生物及其制备方法 |
CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
CN106188022A (zh) * | 2015-04-30 | 2016-12-07 | 上海医药工业研究院 | 伊格列净的制备方法 |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
EA202190226A1 (ru) | 2018-07-19 | 2021-06-16 | Астразенека Аб | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ |
WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
EP4315350A1 (en) | 2021-04-01 | 2024-02-07 | AstraZeneca UK Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1075626B (de) * | 1960-02-18 | Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M | Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden | |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
ES2254376T3 (es) * | 2000-03-17 | 2006-06-16 | Kissei Pharmaceutical Co., Ltd. | Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados. |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
CN1293087C (zh) * | 2000-09-29 | 2007-01-03 | 橘生药品工业株式会社 | 吡喃葡糖氧基苄基苯衍生物及其药物组合物 |
CA2429833A1 (en) * | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
SK287786B6 (sk) | 2000-12-28 | 2011-09-05 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie |
TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
EP1432720A1 (en) * | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2004
- 2004-07-29 UA UAA200605348A patent/UA86042C2/ru unknown
- 2004-07-30 UA UAA200605346A patent/UA87991C2/ru unknown
- 2004-07-30 EP EP04771313.6A patent/EP1654269B1/en not_active Not-in-force
- 2004-07-30 WO PCT/JP2004/011311 patent/WO2005012321A1/en active Application Filing
- 2004-07-30 UA UAA200602256A patent/UA83377C2/uk unknown
- 2004-07-30 BR BRPI0413233-5A patent/BRPI0413233A/pt not_active IP Right Cessation
- 2004-07-30 EA EA200600348A patent/EA011025B1/ru not_active IP Right Cessation
- 2004-07-30 UA UAA200605347A patent/UA85569C2/ru unknown
- 2004-07-30 UA UAA200605349A patent/UA86599C2/ru unknown
- 2004-07-30 ES ES04771313.6T patent/ES2527053T3/es active Active
- 2004-07-30 US US10/566,585 patent/US7521430B2/en not_active Expired - Fee Related
- 2004-07-30 TW TW093122844A patent/TWI377209B/zh not_active IP Right Cessation
- 2004-07-30 AU AU2004260760A patent/AU2004260760B2/en not_active Ceased
- 2004-07-30 KR KR1020067002158A patent/KR101101500B1/ko not_active IP Right Cessation
- 2004-07-30 NZ NZ545305A patent/NZ545305A/en not_active IP Right Cessation
- 2004-07-30 JP JP2006519250A patent/JP4717811B2/ja not_active Expired - Fee Related
- 2004-07-30 MX MXPA06001273A patent/MXPA06001273A/es active IP Right Grant
- 2004-07-30 CN CNA2004800220063A patent/CN1829728A/zh active Pending
- 2004-07-30 CN CN2010105463425A patent/CN102060888A/zh active Pending
- 2004-07-30 CA CA2534022A patent/CA2534022C/en not_active Expired - Fee Related
-
2006
- 2006-01-10 IL IL173051A patent/IL173051A/en not_active IP Right Cessation
- 2006-01-16 NO NO20060219A patent/NO333679B1/no not_active IP Right Cessation
- 2006-02-27 ZA ZA200601686A patent/ZA200601686B/en unknown
- 2006-05-15 ZA ZA200603880A patent/ZA200603880B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20060132539A (ko) | 2006-12-21 |
EP1654269B1 (en) | 2014-10-15 |
TW200510440A (en) | 2005-03-16 |
KR101101500B1 (ko) | 2012-01-03 |
NO333679B1 (no) | 2013-08-05 |
UA83377C2 (uk) | 2008-07-10 |
AU2004260760B2 (en) | 2009-08-13 |
CN1829728A (zh) | 2006-09-06 |
CA2534022A1 (en) | 2005-02-10 |
UA85569C2 (ru) | 2009-02-10 |
EA200600348A1 (ru) | 2006-08-25 |
BRPI0413233A (pt) | 2006-10-03 |
JP4717811B2 (ja) | 2011-07-06 |
TWI377209B (en) | 2012-11-21 |
ZA200601686B (en) | 2007-05-30 |
US20070060545A1 (en) | 2007-03-15 |
CN102060888A (zh) | 2011-05-18 |
WO2005012321A1 (en) | 2005-02-10 |
EP1654269A1 (en) | 2006-05-10 |
UA86042C2 (en) | 2009-03-25 |
IL173051A0 (en) | 2006-06-11 |
UA87991C2 (en) | 2009-09-10 |
CA2534022C (en) | 2012-10-02 |
NZ545305A (en) | 2008-11-28 |
AU2004260760A1 (en) | 2005-02-10 |
US7521430B2 (en) | 2009-04-21 |
ES2527053T3 (es) | 2015-01-20 |
IL173051A (en) | 2012-06-28 |
EA011025B1 (ru) | 2008-12-30 |
ZA200603880B (en) | 2010-01-27 |
UA86599C2 (en) | 2009-05-12 |
NO20060219L (no) | 2006-04-28 |
JP2007518682A (ja) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06001273A (es) | Compuestos novedosos. | |
MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
EP1206935A4 (en) | TH2 DIFFERENTIAL INHIBITION | |
HK1069395A1 (en) | Phthalazinone derivatives 2,3 | |
IL155702A0 (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor | |
DE60336850D1 (en) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
AU2002246728A1 (en) | Carboline derivatives | |
LT2003017A (en) | Polymorphs of an epothilone analog | |
HK1133002A1 (es) | ||
WO2003024441A1 (fr) | Nouvelle utilisation de composes tricycliques | |
AU2002249890A1 (en) | Carboline derivatives | |
YU39803A (sh) | Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora | |
TW200626145A (en) | Heterocyclic compounds and thrombopoietin receptor activators | |
AU2003239389A1 (en) | Opioid receptor antagonists | |
MY140749A (en) | Novel piperidine compound | |
NO20052023L (no) | Kalsium aktivert K kanal apner med hoy konduktans | |
MY138826A (en) | 2,7-substituted indoles | |
WO2003004497A1 (fr) | Compose heterocyclique | |
BR0209901A (pt) | Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina | |
EP1786815A4 (en) | SPIRO COMPOUNDS AND METHOD FOR MODULATING CHEMOKIN RECEPTOR ACTIVITY | |
AU2002211493A1 (en) | Indole derivatives as pde5-inhibitors | |
WO2003093247A3 (en) | Antibacterial agents | |
MXPA05006957A (es) | Nuevos derivados de fosforamida. | |
EP1211253A4 (en) | DIHYDROBENZOFURAN TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND AGENTS | |
MXPA03000887A (es) | Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status | ||
FG | Grant or registration |